文献速递乳腺癌

乳腺筛查中数字断层合成联合数字乳腺摄影或合成二维乳腺摄影的准确性比较:MAITA随机对照试验联盟的基线结果

Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium.
PubMed 文献 · Eur J Cancer · 2024-01-17

MAITA联盟纳入四项意大利随机试验,比较数字断层合成(DBT)联合数字乳腺摄影(DM)或合成二维(synthetic-2D)与单独DM的筛查性能。2014年3月至2022年2月,50,856名和63,295名45至69岁女性分别随机至DBT组和DM组。DBT组召回率更高(5.84%对4.96%),癌症检出率提高51%,即每1000人多检出2.6例癌症(95%CI 1.7至3.6)。

要点

  • DBT组召回率5.84%,DM组4.96%,差异因中心而异。
  • DBT组每1000人多检出2.6例癌症(95%CI 1.7至3.6),相对增加51%。
  • DBT组每1000人多0.8例(95%CI 0.3至1.3)因良性病变接受手术治疗。

核心结论

  • MAITA结果证实DBT在癌症检出方面优于DM,但召回率可能增加。
  • 在等待晚期癌症发病率影响长期随访结果期间,DBT的筛查性能应本地评估。

研究设计与样本

  • MAITA是四项意大利试验(REtomo、Proteus、Impeto和MAITA trial)的联盟,采用两臂随机设计。
  • REtomo和Proteus比较DBT联合DM与DM,Impeto和MAITA trial比较DBT联合合成二维与DM,纳入多个厂商设备。
  • 45至69岁女性被个体随机分配接受一轮DBT或DM筛查。
  • 2014年3月至2022年2月,50,856名女性随机至DBT组,63,295名女性随机至DM组。
  • DBT组中6,656名女性接受DBT联合合成二维筛查。

主要发现

  • DBT组召回率为5.84%,DM组为4.96%,中心间存在差异。
  • DBT组每1000人多0.8名女性(95%CI 0.3至1.3)因良性病变接受手术治疗。
  • DBT组癌症检出率相对增加51%,即每1000人多检出2.6例癌症(95%CI 1.7至3.6),浸润性癌和导管原位癌的相对增加相似。
  • 在50岁以下和50岁以上、首轮和后续轮次、以及DBT联合DM和DBT联合合成二维中,结果相似;未观察到明显学习曲线。
  • 两组检测≥20 mm、≥2个阳性淋巴结、III级、HER2阳性或三阴性癌症的结果相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The analyses here reported aim to compare the screening performance of digital tomosynthesis (DBT) versus mammography (DM). METHODS: MAITA is a consortium of four Italian trials, REtomo, Proteus, Impeto, and MAITA trial. The trials adopted a two-arm randomised design comparing DBT plus DM (REtomo and Proteus) or synthetic-2D (Impeto and MAITA trial) versus DM; multiple vendors were included. Women aged 45 to 69 years were individually randomised to one round of DBT or DM. FINDINGS: From March 2014 to February 2022, 50,856 and 63,295 women were randomised to the DBT and DM arm, respectively. In the DBT arm, 6656 women were screened with DBT plus synthetic-2D. Recall was higher in the DBT arm (5·84% versus 4·96%), with differences between centres. With DBT, 0·8/1000 (95% CI 0·3 to 1·3) more women received surgical treatment for a benign lesion. The detection rate was 51% higher with DBT, ie. 2·6/1000 (95% CI 1·7 to 3·6) more cancers detected, with a similar relative increase for invasive cancers and ductal carcinoma in situ. The results were similar below and over the age of 50, at first and subsequent rounds, and with DBT plus DM and DBT plus synthetic-2D. No learning curve was appreciable. Detection of cancers >= 20 mm, with 2 or more positive lymph nodes, grade III, HER2-positive, or triple-negative was similar in the two arms. INTERPRETATION: Results from MAITA confirm that DBT is superior to DM for the detection of cancers, with a possible increase in recall rate. DBT performance in screening should be assessed locally while waiting for long-term follow-up results on the impact of advanced cancer incidence.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Giorgi Rossi P, Mancuso P, Pattacini P, et al. Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium. Eur J Cancer. 2024. PMID: 38262307. doi:10.1016/j.ejca.2024.113553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。